938 related articles for article (PubMed ID: 26090067)
61. The risk of transfusion-transmitted infections in sub-Saharan Africa.
Jayaraman S; Chalabi Z; Perel P; Guerriero C; Roberts I
Transfusion; 2010 Feb; 50(2):433-42. PubMed ID: 19843290
[TBL] [Abstract][Full Text] [Related]
62. [Significance of alanine aminotransferase screening in blood donors for risk reduction of hepatitis B and C transmission by haemotherapy].
Kusendová K; Gavorník P; Sabaka P; Sviteková K
Vnitr Lek; 2016 Jan; 62(1):9-16. PubMed ID: 26967232
[TBL] [Abstract][Full Text] [Related]
63. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.
Weusten JJ; van Drimmelen HA; Lelie PN
Transfusion; 2002 May; 42(5):537-48. PubMed ID: 12084161
[TBL] [Abstract][Full Text] [Related]
64. [Screening for viral genomes in blood transfusion].
Coste J
Transfus Clin Biol; 2000 Jun; 7 Suppl 1():11s-17s. PubMed ID: 10919218
[TBL] [Abstract][Full Text] [Related]
65. [Seroprevalence of viral markers among blood donors at the Blood Donor Center of Mohammed V Military Teaching Hospital of Rabat, Morocco].
Uwingabiye J; Zahid H; Unyendje L; Hadef R
Pan Afr Med J; 2016; 25():185. PubMed ID: 28292147
[TBL] [Abstract][Full Text] [Related]
66. Seroepidemiological Study of Hepatitis B, C and HIV among Blood Donors in Kerman.
Mohsenizadeh M; Mollaei HR; Ghaziizadeh M
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3267-3272. PubMed ID: 29286218
[TBL] [Abstract][Full Text] [Related]
67. [Genetic diversity of viruses. Consequences for screening and prevention].
Barin F; Laperche S; Couroucé AM
Transfus Clin Biol; 2000 Oct; 7(5):472-8. PubMed ID: 11109632
[TBL] [Abstract][Full Text] [Related]
68. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS).
Glynn SA; Kleinman SH; Schreiber GB; Busch MP; Wright DJ; Smith JW; Nass CC; Williams AE
JAMA; 2000 Jul; 284(2):229-35. PubMed ID: 10889598
[TBL] [Abstract][Full Text] [Related]
69. Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania.
Franzeck FC; Ngwale R; Msongole B; Hamisi M; Abdul O; Henning L; Letang E; Mwaigomole G; Battegay M; Hatz C; Tanner M
PLoS One; 2013; 8(3):e58468. PubMed ID: 23469281
[TBL] [Abstract][Full Text] [Related]
70. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.
Davidson T; Ekermo B; Gaines H; Lesko B; Åkerlind B
Transfusion; 2011 Feb; 51(2):421-9. PubMed ID: 20849409
[TBL] [Abstract][Full Text] [Related]
71. Detection of HIV-1, HBV and HCV antibodies in blood donors from Surat, western India.
Nandi J; Bhawalkar V; Mody H; Elavia A; Desai PK; Banerjee K
Vox Sang; 1994; 67(4):406-7. PubMed ID: 7535499
[TBL] [Abstract][Full Text] [Related]
72. Seroprevalence of hepatitis B, hepatitis C and HIV infection among patients undergoing haemodialysis in Buenos Aires, Argentina.
Pereson MJ; Martínez AP; Isaac K; Laham G; Ridruejo E; Garcia GH; Flichman DM; Di Lello FA
J Med Microbiol; 2021 Jan; 70(1):. PubMed ID: 33180017
[No Abstract] [Full Text] [Related]
73. Evaluation of surrogate markers for human immunodeficiency virus infection among blood donors at the blood bank of "Hospital Universitário Regional Norte do Paraná", Londrina, PR, Brazil.
Reiche EM; Vogler IH; Morimoto HK; Bortoliero AL; Matsuo T; Yuahasi KK; Cancian SJ; Koguichi RS
Rev Inst Med Trop Sao Paulo; 2003; 45(1):23-7. PubMed ID: 12751318
[TBL] [Abstract][Full Text] [Related]
74. Performance of rapid diagnostic tests for detection of Hepatitis B and C markers in HIV infected patients.
Barbosa JR; Colares JKB; Flores GL; Cortes VF; Miguel JC; Portilho MM; Marques VA; Potsch DV; Brandão-Mello CE; Amendola-Pires M; Pilotto JH; Lima DM; Lampe E; Villar LM
J Virol Methods; 2017 Oct; 248():244-249. PubMed ID: 28782578
[TBL] [Abstract][Full Text] [Related]
75. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M
Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489
[TBL] [Abstract][Full Text] [Related]
76. Prevalence of seromarkers of HBV and HCV among blood donors in eastern Saudi Arabia, 1998-2001.
Bashawri LA; Fawaz NA; Ahmad MS; Qadi AA; Almawi WY
Clin Lab Haematol; 2004 Jun; 26(3):225-8. PubMed ID: 15163322
[TBL] [Abstract][Full Text] [Related]
77. Occult hepatitis B virus infection: implications in transfusion.
Allain JP
Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
[TBL] [Abstract][Full Text] [Related]
78. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study.
Rouet F; Chaix ML; Inwoley A; Msellati P; Viho I; Combe P; Leroy V; Dabis F; Rouzioux C;
J Med Virol; 2004 Sep; 74(1):34-40. PubMed ID: 15258966
[TBL] [Abstract][Full Text] [Related]
79. Comparison of different rapid screening tests and ELISA for HBV, HCV, and HIV among healthy blood donors and recipients at Jibla University Hospital Yemen.
Al-Matary AM; Al Gashaa FAS
J Med Life; 2022 Nov; 15(11):1403-1408. PubMed ID: 36567845
[TBL] [Abstract][Full Text] [Related]
80. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
